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 2 
Abstract  
Varicella-zoster virus (VZV) causes chickenpox and shingles, and is found in human 
populations worldwide. The lack of temporal signal in the diversity of VZV makes 
substitution rate estimates unreliable, which is a barrier to understanding the context 
of its global spread. Here, we estimate rates of evolution by studying live attenuated 
vaccines, which evolved in 22 vaccinated patients for known periods of time, 
sometimes, but not always undergoing latency. We show that the attenuated virus 
evolves rapidly (~10-6 substitutions/site/day), but that rates decrease dramatically 
when the virus undergoes latency. These data are best explained by a model in 
which viral populations evolve for around 13 days before becoming latent, but then 
undergo no replication during latency. This implies that rates of viral evolution will 
depend strongly on transmission patterns. Nevertheless, we show that implausibly 
long latency periods are required to date the most recent common ancestor of extant 
VZV to an “out-of-Africa” migration with humans, as has been previously suggested. 
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Introduction  
Varicella zoster virus (VZV; also known as human herpesvirus 3) is a nuclear-
replicating double-stranded DNA virus, with a genome of around 125kb and over 70 
open reading frames (ORFs). The virus is the causative agent of varicella (chicken 
pox), and herpes zoster (shingles), two conditions that can lead to serious 
complications (World Health Organization 1998; Gilden et al. 2011).  
The global genetic diversity of VZV is now well characterized, with five major clades 
segregating geographically (Muir, Nichols, Breuer 2002; Schmidt-Chanasit, Sauerbrei 
2011; Grose 2012; Zell et al. 2012; Chow, Tipples, Grose 2013). But while its 
phylogeny is well resolved, there is less certainty about the age of VZV’s most recent 
common ancestor, and this is a major impediment to understanding its origins and 
the ecological context of its global spread. 
For example, Zell et al. (2012) analyzed VZV along with other alphaherpesvirinae 
(see also(McGeoch, Cook 1994; Muir, Nichols, Breuer 2002; Grose 2012)), and 
showed that the viral phylogeny agreed exactly with the phylogeny of their 
mammalian hosts (Meredith et al. 2011), suggestive of host-virus co-speciation. 
Calibration of the viral phylogeny with the mammalian fossil record, placed the most 
recent common ancestor of VZV at ~110,000 years ago. This date is consistent with 
the prominent theory that VZV spread around the globe by accompanying humans on 
their out-of-Africa migrations (Grose 1999; Petraglia et al. 2010; Grose 2012) - a 
pattern also observed in other pathogens (Moodley et al. 2012; Paraskevis et al. 
2013). In contrast, Firth et al. (2010), analyzed viruses sampled from around the 
world over a 37-year period, and, using a method of dated tips (Rambaut 2000), 
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estimated that the most recent common ancestor of VZV lived just 309 years ago 
(95% highest posterior density 51-741).  
Such wildly different rate estimates have been remarkably common in the study of 
viruses, suggesting that something is severely wrong with our assumptions about 
their evolution (Holmes 2003; Sharp, Simmonds 2011; Lythgoe, Fraser 2012). In fact, 
as the authors recognize, there are good reasons to doubt both previous estimates 
for the age of VZV. Specifically, Firth et al.’s (2010) method of dated tips relies on 
datasets showing sufficient temporal signal, but despite VZV samples obtained over 
37 years, randomization of the sampling dates provided similar estimates, suggesting 
that true temporal signal was absent. In contrast, estimates based on cospeciation 
have used a calibration point at ~24 million ybp (the Old World Monkey-ape split, 
assumed to coincide with the divergence between Herpes simplex and Macacine 
herpesvirus 1 (Zalmout et al. 2010)). This calibration is over 200 times older than the 
date of interest, which can cause problems, e.g., with saturation of informative sites 
(Linder, Hardy, Rutschmann 2005; Duchêne, Holmes, Ho 2014). Furthermore, such 
analyses must rely on the assumption that rates of viral evolution have remained 
roughly constant over the entire 24myr period. 
Another difficulty with dating viral origins is the time-dependency of evolutionary rate 
estimates (Ho, Larson 2006; Ho et al. 2011; Sharp, Simmonds 2011; Lythgoe, Fraser 
2012). This may be a general phenomenon with several causes (Ho et al. 2011), but 
one factor might be uniquely important in viral evolution, namely viral latency, i.e., the 
ability of pathogenic viruses to lay dormant in the cell. Indeed, several authors have 
suggested that long periods of latency, with little or reduced viral replication, might 
reconcile the observations of rapid rates of evolution over short periods and the 
slower rates implied by plausible biogeographical scenarios (Kelly 1994; Jenkins et 
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al. 2002; Holmes 2003; Switzer et al. 2005; Ramsden et al. 2008; Sharp, Simmonds 
2011; Lythgoe, Fraser 2012). This could be an important factor in VZV evolution, as it 
undergoes periods of latency in neurons (particularly in the trigeminal and dorsal 
nerves). Indeed, herpes zoster is the result of viral reactivation following latency 
(Gilden et al. 2011). But whilst comparative evidence shows that viruses causing 
latent infection evolve significantly more slowly than viruses with acute or persistent 
infections (Hanada, Suzuki, Gojobori 2004), we lack evidence that latency is directly 
affecting evolutionary rates in any single case.  
Here, we take a novel approach to investigating the effects of latency on evolutionary 
rates, by tracking the within-patient evolution of VZV vaccines (Depledge et al. 2013). 
The vOka vaccine, which was developed in the 1970s (Takahash et al. 1974), is a 
live attenuated virus. As such, it is free to evolve in patients following their 
vaccination (Kanda et al. 2011; Quinlivan, Breuer, Schmidt 2011; Depledge et al. 
2013). Vaccination can also cause side effects in some cases. In particular, ~5% of 
vaccinated healthy children experience an attenuated form of the varicella rash 
(Sharrar et al. 2000; Galea et al. 2008; Goulleret et al. 2010), while a smaller number 
of patients experience latent infection (zoster) as a direct result of the vaccination 
(Civen et al. 2009). 
Within-patient evolution of the VZV vaccine has attracted attention because of its 
possible role in causing disease (e.g., following reversion towards the wild-type 
(Quinlivan, Breuer, Schmidt 2011; Depledge et al. 2013)), but the viral genomes also 
allow us to study replicated instances of viral evolution over a known time period. 
Because some of the vaccine genotypes have established latency and reactivated 
before sampling, the data also allow us to estimate the effects of latency on 
evolutionary rates. 
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Results 
Analysis of Vaccine batches and inference of the ancestral sequence 
To estimate the amount of evolutionary change that has accrued in each patient, we 
must first infer the genome sequence of the vaccine that was administered to that 
patient. To this end, we compared whole genome sequences of different batches of 
the vOka vaccine (Table 1). Specifically, we compared three modern vaccine batches 
(obtained between 2009-2012 in the USA and UK), to an early batch from 1986. 
These vaccine batches therefore approximately span the dates of our patient 
samples (1982-2013; Table 1). In an alignment of over 100kb, we found no fixed 
differences between any of the vaccine strains, and this remained true when we 
excluded polymorphic variants segregating at frequencies below 10%.   
This suggests that the process of culturing, by which vaccine batches are derived 
from a common frozen seed stock), is not introducing substantial evolutionary 
change, and this suggests that the sequences of the modern vaccine batches will be 
very close to that administered to the patients. However, all of the vaccine batches 
did contain genetic variation (Table S1), and so variable vaccine sequences are likely 
to have been injected into patients (Depledge et al. 2013). Failure to account for such 
variation could upwardly bias our estimates of evolutionary rates (Nei 1971), although 
the extent of such an artefact will depend on the profile of the genetic variation within 
the vaccine. 
The bias will be weakest if the genetic variation in the vaccines mostly comprises 
deleterious mutations. Such variation should contribute little to within-patient 
evolution, since deleterious mutations segregate at low frequencies, but rarely reach 
fixation. Previous results suggest that most variation in VZV vaccines is indeed 
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deleterious (Depledge et al. 2013), and so for our major analyses, we used the 
consensus sequence of the three modern vaccine batches as our assumed ancestral 
genome. 
However, a stronger bias would arise if some of the injected variants were selectively 
neutral or beneficial once inside the patient (Depledge et al. 2013). Accordingly, to 
minimize the effects of ancestral polymorphism, we repeated all analyses using only 
sites that were fixed in all four vaccine batches (including the early batch). Of course, 
this approach might still miss very low frequency variants, but such variants are 
expected to have the least effect on rate estimates, essentially because low 
frequency variants are likely to have arisen only a few viral replications before 
vaccination (Nei 1971). 
A far larger artefact could arise if secondary infections with VZV were mistakenly 
interpreted as populations that derived from the vaccine. To exclude this possibility, 
we confirmed that each sample was more closely related to the vOka vaccine strain 
than to any published genome of wild-type VZV (Zell et al. 2012), and that all carried 
the diagnostic SNPs reported by (Quinlivan, Breuer, Schmidt 2011). As the vaccine 
was originally derived from naturally occurring VZV of East Asian origin (Takahash et 
al. 1974), the patient samples were particularly distantly related to naturally occurring 
strains from the USA and UK, where our samples were collected (Kanda et al. 2011; 
Quinlivan, Breuer, Schmidt 2011; Zell et al. 2012; Chow, Tipples, Grose 2013; 
Depledge et al. 2013). 
As a final check, we also tested for shared variants between the patient samples, 
since genuine post-vaccination evolution would proceed independently in each 
patient. We found that the majority of variants observed (118/176=67%) were present 
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in no more than a single patient, while 95% of the variants were present in fewer than 
five of the 22 strains. This is consistent with our assumption that the evolutionary 
changes we inferred were indeed accrued after vaccination (see also below). 
 
Evolutionary rates in patients who developed varicella rashes 
For each of our 22 patient samples, we know the length of time between vaccination 
and sampling of VZV genomes from the resulting rash (Table 1). By comparing the 
genomes from these samples to the (inferred) sequence of the initial vaccine, we 
estimated the rate of evolution of the attenuated virus within the patient. 
First, consider the eight samples from patients who developed a varicella rash, 
and thus were sampled before any viral latency (Table 1). Rate estimates can be 
misled by the inclusion of low frequency polymorphic variants in the patient samples, 
because these can represent sequencing errors, or mildly deleterious 
polymorphisms, which violate the assumptions of our rate estimator (e.g., (Eyre-
Walker 2002); see also supporting information). Accordingly, we obtained maximum 
likelihood estimates with polymorphisms excluded below a range of cut-off 
frequencies. These estimates are shown in the left-hand panel of Figure 1. Rate 
estimates are clearly substantially higher when polymorphic variants segregating at 
5% or below were included in the analysis. This is consistent with evidence that low 
frequency variants are often sequencing errors ((Depledge et al. 2013); Figure S1). 
In contrast, estimates were very stable at cut-off frequencies of 10% or above and 
consistently suggested a rate of ~6.36×10-6 substitutions/site/day (CIs: 5.22-7.70×10-
6; all rates here and below are reported with the 10% cut-off, unless otherwise 
specified). Furthermore, rate estimates for all the patient samples were similar 
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(Figure S2a), and there was no evidence of significant between-patient rate variation 
(Likelihood Ratio Test, ΔlnL=13.28, df=7, p = 0.07). The constancy of the rate 
estimates between patients gives us some confidence that the estimates are not 
being greatly inflated by genetic variation in the vaccine samples, since this artefact 
would yield a constant amount of apparent evolution, rather than a constant rate, 
implying a steady increase in evolutionary change with time. 
To further determine the robustness of our estimates, we carried out several 
additional analyses. First, we re-estimated the rate after excluding three samples 
(A171B, A182B and A185B; Table 1) that had been subject to extensive laboratory 
passaging prior to sequencing. Estimates were little changed (Figure 1), suggesting 
that neither passaging, nor the use of the older GaIIX sequencing technology for 
some of the samples (Table 1) were greatly affecting estimates once low frequency 
variants were removed (Depledge et al. 2013). 
Second, we repeated estimates excluding any site that was found to be 
polymorphic in any of our four vaccine batches. This is a much more conservative 
approach to accounting for genetic variation in the vaccine (see above). However, 
the procedure is also likely to artefactually decrease estimates, by excluding sites 
under low levels of selective constraint, and so most likely to contribute to evolution. 
Whatever the cause, including only fixed vaccine sites decreased estimates more 
than 3-fold to 1.71×10-6 substitutions/site/day (CIs 1.17-2.43×10-6; Figure 1); and 
again there was no evidence of variation in rate between patients (ΔlnL=1.66, df=7, p 
= 0.97).  
Finally, estimates of evolutionary rates over short time periods might be inflated by 
the inclusion of mutations that are under weak purifying selection, and so unlikely to 
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contribute to evolution over longer time periods (Ho et al. 2011). To test for 
ineffective purifying selection, we repeated both analyses estimating rates for 
synonymous and non-synonymous changes in protein-coding genes (grey symbols in 
Figure 1). Rates were faster than the genomic average at synonymous sites and 
slower at non-synonymous sites, which is consistent with greater levels of purifying 
selection acting on amino-acid changing mutations. And while dn/ds ratios are high 
(0.59 for all vaccine sites, and 0.32 at fixed vaccine sites), they are similar to 
estimates from the global diversity of VZV (posterior median dn/ds = 0.31, 95% HPD 
0.25-0.38; see below), suggesting that purifying selection is effective, despite the 
short time periods (Ho, Larson 2006). 
 
Evolutionary rates in patients who developed zoster 
Results are radically altered when analyses were repeated with the 14 samples from 
patients who developed herpes zoster (i.e., where vaccine genotypes had undergone 
latency prior to sampling). While the qualitative patterns in the data were similar 
(Figure S3), the single best-fit rate was between one and two orders of magnitude 
slower (~3.18×10-7 substitutions/site/day with all sites included or ~1.09×10-7 
substitutions/site/day with fixed vaccine sites only). Furthermore, there was very 
strong evidence of rate variation between patients (ΔlnL=150.89, df=13, p < 10-6), 
and estimates from individual patients varied from 1.10×10-7, to 2.07×10-6 
subs./site/day (see Figure S2b). 
Most notably, in contrast to the varicella samples (Figure 2a), the estimated rates of 
evolution for the zoster samples decreased linearly with the length of time between 
vaccination and the appearance of symptoms (Figure 2b). This pattern suggests that 
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the variable rates are due to similar amounts of evolution taking place in each 
patient, despite the very different times between vaccination and the appearance of 
herpes zoster. Indeed, model selection with the Bayesian Information Criterion 
suggests that a model with a fixed amount of evolution provides a substantially better 
fit to the zoster patient data than a model with a fixed rate of evolution or a model 
with variable rates (BIC values: single amount 193.8, single rate 318.2, variable rates 
219.6). 
A natural interpretation for these results is that, following vaccination, the attenuated 
virus evolves for a fixed amount of time either before and/or after establishing a latent 
infection. Once latent, replication is arrested so that no new mutations accumulate, 
regardless of the period of time spent within the host. If this interpretation is correct, 
then we can estimate this “duration of active viral replication” directly from our data, 
by assuming that all 22 of our samples evolved at the same rate when they were 
active (see supporting information). Taking all 14 zoster samples together, we 
estimate this duration to be t* = 13.3 days (CIs: 10.9-15.9; individual estimates range 
between 2.9 and 27.6 days). 
Latency and dating the most recent common ancestor of VZV’s global diversity 
Results above show that changes in viral latency periods can substantially alter 
evolutionary rates. This implies that rates estimated over very short-term periods 
might not be reliable if extrapolated back to the origins of VZV. It also questions 
dates inferred from the complete alphaherpesvirinae phylogeny, which assume that 
rates remained roughly constant for millions of years before the origin of VZV. 
Accordingly, to investigate the global spread of VZV we reanalyzed published 
whole genome data, representing the global diversity of the virus (Zell et al. 2012). 
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Because these data were sampled over a 44-year period (1964-2008; see Table S2), 
temporal signal in the data might be used to date the phylogeny(Rambaut 2000; Firth 
et al. 2010). If rates of evolution were relatively constant over the sampling period, 
then we would expect earlier samples to have undergone less molecular evolution. 
However, analyses reported in the supporting information found no evidence of such 
a pattern (see also (Firth et al. 2010)), supporting our suggestion that variation in 
transmission patterns can lead to erratic rate variation in VZV over short time 
periods. 
Because past transmission patterns are unknown to us, it is difficult to date the 
spread of VZV with much certainty. However, we can ask whether a hypothesized 
date of the most recent common ancestor is consistent with plausible transmission 
dynamics.  
To do this, we first identified segments of the VZV genome with no evidence of 
recombination (Figure S5), and then reconstructed the evolutionary history of these 
segments using Bayesian phylogenetics, and a relaxed molecular clock. To constrain 
the evolutionary rate of VZV in these analyses, we used the following equation, which 
relates short- and long-term rates (i.e., rates with and without latency effects). 
€ 
µ long =
µshort t*
avg. time between infections,    (1) 
where the numerator is the expected amount of evolutionary change accrued while 
the virus is replicating, and the denominator is the expected time between infections 
(including both replication and latency periods). We then made several assumptions 
to bias our analysis towards an older date estimate: (i) we used the slower of our 
short-term rate estimates (µshort = 1.71×10-6; Figure 1), obtained by excluding any site 
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that was polymorphic in the vaccine; (ii) we used the lower bound of our estimate of 
the duration of active viral replication (t* = 10.9 days); (iii) we assumed an average 
50-year gap between transmissions, which is consistent with some observed latency 
periods (Yawn et al. 2007; Weitzman et al. 2013), but ignores the possibility of 
varicella-to-varicella transmissions which occur without latency; and (iv) we applied 
our long-term rate solely to third positions in protein-coding genes, thereby allowing 
other sites in the genome to evolve more slowly. 
 Results of our dating analyses are shown in Figure 3. The phylogenies 
indicate the major clades of VZV, as identified by (Zell et al. 2012); see also Figure 
S5), and each phylogeny applies to a different segment of the VZV genome, together 
comprising ~85% of its total length. The phylogenetic topologies of the two genomic 
segments differ substantially, suggesting that they have recombined since the origins 
of the virus (McGeoch, Cook 1994; Loparev et al. 2007; Zell et al. 2012). However, 
the estimated dates of the most recent common ancestors are remarkably similar 
(segment 1: 4904 ybp; segment 2: 4880 ybp). Most importantly, despite our biasing 
results towards older date estimates, both dates are significantly younger than the 
youngest possible dates for the out-of-Africa migrations of modern humans(Petraglia 
et al. 2010). 
To confirm this, we repeated our analyses, making no assumptions about 
long-term rate, but constraining the most recent common ancestor of VZV to 110,000 
ybp – the date obtained by (Zell et al. 2012), which would be consistent with the out-
of-Africa hypothesis. This analysis estimated an average long-term rate of 3.74×10-7 
subs./site/year. With the foregoing assumptions about short-term rates, a long-term 
rate this slow would require an average between-transmission time of 1112 years – 
which is clearly implausible.
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Discussion 
We have studied the evolution of the Varicella-zoster virus vaccine within 
patients. Using the unique biology of VZV, and the availability of a well characterized 
live attenuated vaccine, we have shown that viral latency halts the molecular 
evolution of the virus. This, to our knowledge, is the first direct evidence that latency 
can reduce evolutionary rates in a single virus species (Holmes 2003; Hanada, 
Suzuki, Gojobori 2004; Switzer et al. 2005; Sharp, Simmonds 2011; Lythgoe, Fraser 
2012) 
We have also provided a rate estimate for the vaccine in the absence of latency 
effects. At ~10-3 substitutions per site per year (~10-6 per site per day), our estimates 
are congruent with some estimates from double-stranded DNA phage (Minot et al. 
2013), but are around 10 times faster than typical short-term evolutionary rates of 
double-stranded DNA viruses, as inferred from dated tips dating of between-patient 
data (Fig. S7). It is possible that viral latency is one cause of this discrepancy, as 
latency might have occurred in many published viral data sets, but has certainly not 
occurred for patients who developed varicella rashes following vaccination.  
 
Together, our results have implications for understanding VZV biology. In 
particular, the strong effect of latency on rates implies that VZV does not return to 
latency following activation, despite the asymptomatic shedding of VZV in saliva 
(Nagel et al. 2011a), and the presence of mRNA transcripts involved in replication in 
latent cells (Nagel et al. 2011b; Ouwendijk et al. 2012). This failure to return to 
latency is a probable contrast to herpes simplex virus, a related human 
alphaherpesvirus (Wilson, Mohr 2012), and is consistent with the hypothesis that 
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replication in the skin or blood is needed for VZV to travel to the nerves (Nagel et al. 
2011a). 
Our results also have implications of understanding VZV evolution. First, the 
effects of latency imply that variation in patterns of transmission will lead directly to 
variation in evolutionary rates within and between VZV lineages. Evidence suggests 
that VZV transmission does indeed vary greatly across the world (Yawn et al. 2007; 
Nichols et al. 2011; Weitzman et al. 2013), and might differ substantially between 
modern and hunter-gatherer societies. Second, fundamental differences in 
transmission biology imply that rates of evolution could vary substantially between 
the alphaherpesvirinae, even when their mutation rate per replication is very similar. 
Together, this implies that standard methods of molecular dating – whether based on 
serially sampled genomes or host-virus co-speciation – may be unreliable when 
applied to global VZV diversity. 
Despite this uncertainty, we have argued that the existing data on latency and 
short-term rates do not support the out-of-Africa scenario for the global spread of 
VZV(Muir, Nichols, Breuer 2002; Petraglia et al. 2010; Grose 2012; Zell et al. 2012). 
Even making very conservative assumptions, our date estimates for the most recent 
common ancestor of VZV were substantially younger than required by the out-of-
Africa hypothesis (Fig. 3). Of course, this conclusion relies on short-term rates 
estimated during vaccinations, and not from natural transmission chains involving the 
wild-type virus. Indeed, the only existing rate estimates from a natural transmission 
chain (from an outbreak in 2000 in Guinea-Bissau, Western Africa), are substantially 
slower than our vaccine estimates, and instead, are more typical of estimates from 
other dsDNA viruses ((Depledge et al. 2014); Fig. S7). Nevertheless, even with these 
slower short-term rates (and assuming that no latency was involved in this 
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transmission chain), implausibly large periods of latency would be required to 
generate the very slow long-term rate (~10-7 subs./site/year) required by the out-of-
Africa hypothesis ((Zell et al. 2012); Figs. S4, S7). 
As such, while VZV might well have been present in ancestral African 
populations, its existing global distribution is unlikely to be explained by patterns of 
migration from those populations. Instead, current evidence points to a more recent 
global spread. This possibility is consistent with the topologies shown in Figure 3 
(where clade 5, which is primarily of African origin(Schmidt-Chanasit, Sauerbrei 
2011), is not basal in either tree), and with evidence that aerosol  transmission has 
led to the spread of the virus through single countries over very short periods of time 
(Hawrami et al. 1997; Quinlivan et al. 2002; Sauerbrei et al. 2011). 
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Materials and Methods 
Patient samples and genome sequencing 
The samples for this study are listed in Table 1, and were obtained from healthy 
children in the community who were sampled as part of the post surveillance vaccine 
studies carried out in the USA (see (Sharrar et al. 2000; Galea et al. 2008) and 
Europe (see (Goulleret et al. 2010)). Ten of the samples (B86, A171B, R43, VR5, R3, 
R52, Q27, ZR2, ZR3, ZR4, and ZR5) are new to this study, while the remaining 16 
were previously described (Depledge et al. 2013). Full details of sequencing library 
preparation, sequencing and variant calling are given in the supporting information.  
Counting fixed and polymorphic differences 
To infer the ancestral vaccine sequence, we used two approaches. First, we 
generated a consensus sequence of the three modern vaccine strains (VVAG, VV10 
and VV12; Table 1), after excluding all low frequency variants (cut-off frequency 
35%) present in each of the samples. Four sites which contained a high frequency 
variant in all three vaccine batches were excluded from the analysis. Second, we 
generated a vaccine sequence that excluded any site that was polymorphic at 
frequency 2% or above in any of the four vaccine batches (Table 1); this led to the 
exclusion of 221 sites. For the patient samples, we used a variety of cut-off allele 
frequencies (see below). After excluding low frequency variants, sites were scored as 
polymorphic within the patient if they carried multiple bases, and as fixed differences 
within the patient if the base(s) differed from that in the ancestral vaccine sequence. 
All counts of polymorphic and fixed differences are contained in Table S1. 
Maximum likelihood rate estimation 
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Rates of evolution are most easily estimated from a single pair of alleles, but each of 
our patient samples represents a genetically variable population of virions. Methods 
to estimate evolutionary rates in such cases can be derived from standard population 
genetics theory, using the joint expectations of the number of polymorphic 
differences in a sample of alleles, and the number of fixed differences that separate 
this sample from a known outgroup (Nei 1971; Welch 2006; Depledge et al. 2011). 
However, existing methods of this kind assume that a known number of alleles have 
been sequenced, which is not the case with viral samples from patients. As such, to 
analyze our data, we have developed a new maximum likelihood estimator of 
evolutionary rates, which assumes that the number of alleles sampled is large, but 
unknown, and that variants were excluded below a certain threshold frequency. This 
method has been implemented in freely available open-source software (see 
supporting information for full details). 
Molecular dating of VZV global diversity 
To investigate the origin of VZV, we reanalyzed publicly available complete genome 
sequences (see Table S2 and references therein). For results reported, we retained 
all 49 published genomes, but results were qualitatively unaltered when analyses 
were repeated excluding samples derived from the vOka vaccine stock (Acc. Nos. 
AB097932 and DQ008354-5), and highly passaged isolates (Acc. Nos. DQ479962-3) 
(Tyler et al. 2007; Zell et al. 2012). The complete set of genomes yielded an 
alignment of 126632 bp with 1049 segregating sites. Given strong evidence of 
recombination in VZV (McGeoch, Cook 1994; Loparev et al. 2007; Schmidt-Chanasit, 
Sauerbrei 2011; Zell et al. 2012), we used phylogenetic tests to identify segments of 
the VZV genome that appear to have evolved over a single genealogy (Kosakovsky 
Pond et al. 2006). To date the origin of each genomic segment, we used the 
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Bayesian phylogenetics package BEAST v. 1.7 (Drummond et al. 2012). Full details 
of the priors and models used in these phylogenetic analyses are given in the 
supporting information. 
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Figure Legends 
Figure 1 
Estimated rates of evolution for the 8 VZV strains sampled from patients that had 
developed varicella rashes after vaccination (Table 1). All rates are maximum 
likelihood estimates with confidence intervals obtained from the likelihood surface. 
The left-hand panel shows results varying the allele cut-off frequency, (denoted c in 
the supporting methods), i.e., alleles found below the indicated frequency in any 
single sample were removed from the analysis. The right-hand panel shows how 
results were affected by removing the three strains that were subjected to passaging 
in the laboratory (black circles); and by removing any site that was polymorphic in 
any of the four vaccine batches (triangles). The grey symbols show estimated rates 
for synonymous changes (empty symbols) and non-synonymous changes (filled 
symbols) in protein coding genes. 
 
Figure 2 
Estimated rates of evolution (substitutions/site/day) for each of the 22 strains of VZV 
sampled from vaccinated patients. Estimated rates are plotted against the length of 
time (days) between vaccination and sampling, which followed the appearance of 
symptoms. Panel (a) shows the 8 patients who developed varicella rashes, with the 
horizontal line showing the maximum likelihood rate for the whole data set. Panel 
(b) shows the 14 patients who developed herpes zoster rashes, with a line with a 
slope of -1, suggesting that the amount, but not the rate, of evolution is roughly 
constant in all strains. 
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Figure 3 
Dated phylogeny of the global diversity of VZV. Shown are Maximum Clade 
Consensus phylogenies for two large segments of the viral genome that show no 
evidence of within-segment recombination. Node labels show posterior support 
values, and red bars represent 95% Credible Intervals on the estimated divergence 
dates. The labelled clades of VZV(Zell et al. 2012) each appeared with 100% 
posterior support. Results were obtained after making several conservative 
assumptions about the evolutionary rate of VZV, nevertheless, the date estimates are 
substantially younger than is implied by the out-of-Africa hypothesis of VZV origins.
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Table 1 Type: either vaccine batch, patient samples from a vaccine varicella rash or 
vaccine zoster rash. Date: year of vaccine batch production or year of vaccination; * 
indicates sample from the USA. Days: time interval between vaccination and rash 
development. Passage: rates of lab passaging prior to sequencing. Acc. no: GenBank 
accession numbers of consensus sequence. 
 
 
 
 
Sample Type Sequencer  Date Days Passage Acc. no 
VVAG  Vaccine MiSeq 2009*  - - KF558383 
VV10 Vaccine MiSeq 2010 - - KF558384 
VV12 Vaccine MiSeq 2012 - - KF558385 
B86 Vaccine HiSeq 1986* - - KF853225 
A171B Varicella GAiix 1988* 14 high KF853226 
A182B Varicella GAiix 1988* 16 high KF558381 
A185B Varicella GAiix 1988* 21 high KF558382 
O27 Varicella GAiix 1999* 16 none KF558376 
VR2 Varicella MiSeq 2007 17 none KF558372 
VR1 Varicella MiSeq 2007 14 none KF558373 
R43  Varicella MiSeq 2000* 23 none KF853229 
VR5 Varicella MiSeq 2008 16 none KF853233 
R3 Zoster GAiix 1999* 244 low KF853228 
R52 Zoster GAiix 1999* 490 low KF853230 
T17 Zoster GAiix 2000* 310 low KF558378 
T25 Zoster GAiix 2000* 547 low KF558379 
v76 Zoster GAiix 1982* 630 low KF558380 
K11 Zoster MiSeq 1997* 75 none KF558391 
L53 Zoster MiSeq 1997* 131 none KF558389 
T61 Zoster GAiix 2001* 91 none KF558377 
ZR1 Zoster MiSeq 2006 330 none KF558371 
Q27 Zoster MiSeq 1998* 541 low KF853227 
ZR2 Zoster MiSeq 2006 150 none KF853231 
ZR3 Zoster MiSeq 2007 577 none KF853232 
ZR4 Zoster MiSeq 2010 517 none KF853234 
ZR5 Zoster MiSeq 2013 120 none KF853235 
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